340 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Early movers: VRX, AGN, W, ODP, PRTY, VZ, WFC, UAL, P & more http://www.cnbc.com/2017/05/09/early-movers-vrx-agn-w-odp-prty-vz-wfc-ual-p-more.html May 09, 2017 - Names on the move ahead of the open.
Allergan (AGN) Beats Q1 Earnings Estimates, Ups 2017 View http://www.zacks.com/stock/news/259943/allergan-agn-beats-q1-earnings-estimates-ups-2017-view?cid=CS-ZC-FT-259943 May 09, 2017 - Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.
Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss http://www.zacks.com/stock/news/259920/ironwood-irwd-q1-loss-wider-than-expected-sales-miss?cid=CS-ZC-FT-259920 May 09, 2017 - Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.
Allergan (AGN) Beats Q1 Earnings & Sales; Ups 2017 View http://www.zacks.com/stock/news/259833/allergan-agn-beats-q1-earnings-sales-ups-2017-view?cid=CS-ZC-FT-259833 May 09, 2017 - Allergan???s first-quarter earnings of $3.35 per share were above our consensus estimate of $3.32 per share.
The Top Earnings Charts to Start the Week http://www.zacks.com/stock/news/259797/the-top-earnings-charts-to-start-the-week?cid=CS-ZC-FT-259797 May 08, 2017 - With so many companies reporting earnings, Tracey wades through all the noise to bring you the best charts.
Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales http://www.zacks.com/stock/news/257769/novartis-tops-q1-earnings-cosentyx-entresto-boost-sales?cid=CS-ZC-FT-257769 Apr 25, 2017 - Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Bleak Outlook for Big Drug Makers https://www.wsj.com/articles/bleak-outlook-for-big-drug-makers-1493051153?mod=rss_markets_main Apr 25, 2017 - Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
3 Healthcare Bargain Stocks You Can Buy Right Now https://www.fool.com/investing/2017/04/24/3-healthcare-bargain-stocks-you-can-buy-right-now.aspx?source=iedfolrf0000001 Apr 24, 2017 - Allergan, Express Scripts, and Vertex stocks look attractive in a generally overpriced market.
Should Gilead Sciences Be Worried About Allergan? https://www.fool.com/investing/2017/04/23/should-gilead-sciences-be-worried-about-allergan.aspx?source=iedfolrf0000001 Apr 23, 2017 - Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
Allergan (AGN) Collaborates with Novartis to Treat NASH http://www.zacks.com/stock/news/256887/allergan-agn-collaborates-with-novartis-to-treat-nash?cid=CS-ZC-FT-256887 Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis

Pages: 1...2425262728293031323334

<<<Page 29>